Research library · checked 2026-04-27

Oral GLP-1 evidence library

A visual research hub for the studies, real-world evidence and regulator updates behind GLP-1 tablets. UK evidence, US approvals, phase 3 trials, real-world studies and safety updates are kept in separate lanes so each source is read for what it can actually prove.

Use these evidence cards to check the strength, country, population and limitation of each item before drawing conclusions about Rybelsus, oral semaglutide, Wegovy tablets, Foundayo or future oral GLP-1s.

Explore evidence cards View source register Current UK answer

How to use this library

Start with the kind of evidence, then the country, then the medicine. A phase 3 obesity trial, a UK diabetes real-world study and a safety update all matter, but they answer different questions.

Trial evidence

Best for controlled efficacy and safety signals in defined populations. It does not automatically answer UK availability.

Real-world evidence

Best for understanding routine clinical use, persistence and practice context. It is usually less controlled than a trial.

Regulator evidence

Best for approval status, label meaning and safety updates. It is the first stop for country-specific claims.

UK evidence US approval Oral semaglutide Orforglipron Regulator safety Sources

Evidence cards

Each card gives you the useful facts first: what was studied, where it applies, what the main signal was, what the limitation is, and what a UK reader should take from it.

UK real-world study

PIONEER REAL UK

UK real-world Rybelsus evidence

High real-world relevance
-1.1% HbA1cMain signal
-4.8 kgScale/context
MedicineRybelsus
Moleculeoral semaglutide
JurisdictionUK
Use studiedType 2 diabetes

Population: Adults with type 2 diabetes in UK routine clinical practice, not previously treated with injectable glucose-lowering medication.

Design: Multicentre, prospective, non-interventional, single-arm real-world study.

Sample and duration: 333 enrolled; 299 completed; 227 on treatment at end of study. 34 to 44 weeks.

Main result: Estimated HbA1c reduction of 1.1 percentage points.

Weight or metabolic signal: Estimated body-weight change of -4.8 kg.

Safety read: No new safety concerns or severe hypoglycaemia cases were reported in the abstract.

Limitation: Single-arm real-world study; useful for UK practice context but not a placebo-controlled efficacy trial.

What this means for a UK reader This is one of the most valuable UK-specific oral semaglutide reference points because it shows how Rybelsus performed in routine UK diabetes care.
PubMed abstract
US real-world study

IGNITE

Early US real-world oral semaglutide use

Moderate real-world relevance
-0.9% HbA1cMain signal
n=782Scale/context
MedicineRybelsus
Moleculeoral semaglutide
JurisdictionUS
Use studiedType 2 diabetes

Population: People with type 2 diabetes initiating oral semaglutide in US routine clinical practice.

Design: Retrospective observational study using electronic health-record data.

Sample and duration: 782 people with type 2 diabetes. Approximately 6 months.

Main result: Reported mean HbA1c reduction of about 0.9 percentage points from baseline.

Weight or metabolic signal: Real-world study included weight outcomes, but the cleanest headline result is HbA1c reduction.

Safety read: Designed to show early routine-practice use; not a dedicated long-term safety trial.

Limitation: Retrospective real-world evidence; dose uptake and follow-up patterns can differ from trials.

What this means for a UK reader Useful for understanding how oral semaglutide translated into early US practice, but UK access and prescribing context still need UK sources.
PMC article / real-world review context
Phase 3 trial

OASIS 1

Oral semaglutide 50 mg for obesity

High trial strength
-15.1% weightMain signal
n=667Scale/context
Medicineoral semaglutide 50 mg
Moleculesemaglutide
JurisdictionGlobal
Use studiedOverweight or obesity without type 2 diabetes

Population: Adults with overweight or obesity without type 2 diabetes.

Design: Randomised, double-blind, placebo-controlled phase 3 trial.

Sample and duration: 667 randomised; 334 oral semaglutide 50 mg and 333 placebo. 68 weeks.

Main result: Estimated mean body-weight change of -15.1% with oral semaglutide 50 mg versus -2.4% with placebo.

Weight or metabolic signal: At least 15% weight reduction occurred in 54% of oral semaglutide participants versus 6% with placebo.

Safety read: Gastrointestinal adverse events were more frequent with oral semaglutide than placebo.

Limitation: Trial dose and obesity indication are not the same as current UK Rybelsus diabetes use.

What this means for a UK reader Important evidence that higher-dose oral semaglutide can produce clinically meaningful weight loss, but it must not be read as current broad UK access.
PubMed / Lancet abstract
Phase 3 trial

OASIS 4

Oral semaglutide 25 mg obesity trial

High trial strength
25 mg dailyMain signal
n=307Scale/context
Medicineoral semaglutide 25 mg
Moleculesemaglutide
JurisdictionGlobal / US relevance
Use studiedOverweight or obesity

Population: Adults without diabetes and with overweight or obesity.

Design: Randomised phase 3 trial of oral semaglutide 25 mg versus placebo plus lifestyle intervention.

Sample and duration: 307 participants; 205 oral semaglutide and 102 placebo. 64 weeks on therapy, with follow-up.

Main result: Oral semaglutide 25 mg produced significantly greater weight loss than placebo.

Weight or metabolic signal: ACC summary describes the weight loss as comparable with high-dose oral and subcutaneous semaglutide versions.

Safety read: Needs to be read with product labels and safety updates before applying to individuals.

Limitation: Trial evidence does not by itself create UK licensing, launch, NHS access or private UK access.

What this means for a UK reader Central to understanding U.S. oral Wegovy-tablet momentum while keeping the UK availability answer separate.
PubMed / ACC summary
Phase 3 trial

PIONEER 1

Oral semaglutide monotherapy in type 2 diabetes

High trial strength
n=703Main signal
26 weeksScale/context
MedicineRybelsus / oral semaglutide
Moleculesemaglutide
JurisdictionGlobal
Use studiedType 2 diabetes

Population: People with type 2 diabetes managed with diet and exercise.

Design: Randomised clinical trial comparing oral semaglutide doses with placebo.

Sample and duration: 703 randomised participants. 26 weeks.

Main result: Oral semaglutide reduced HbA1c in a dose-related way, with the 14 mg dose producing the largest reduction.

Weight or metabolic signal: Body-weight reduction was also reported, strongest at the 14 mg dose.

Safety read: Trial safety profile should be read alongside current product information.

Limitation: Diabetes trial, not a UK weight-loss access study.

What this means for a UK reader Foundational trial evidence behind oral semaglutide as a diabetes medicine.
Clinical review / PubMed-linked data
Head-to-head trial

PIONEER 2

Oral semaglutide versus empagliflozin

High trial strength
vs empagliflozinMain signal
n=822Scale/context
MedicineRybelsus / oral semaglutide
Moleculesemaglutide
JurisdictionGlobal
Use studiedType 2 diabetes

Population: People with type 2 diabetes uncontrolled on metformin.

Design: Randomised trial comparing oral semaglutide 14 mg with empagliflozin 25 mg.

Sample and duration: 822 participants in the PIONEER 2 trial. 52 weeks.

Main result: HbA1c reduction significantly favoured oral semaglutide at week 26 and week 52.

Weight or metabolic signal: Body-weight results are part of the comparative trial evidence.

Safety read: Head-to-head diabetes trial; safety interpretation belongs with product information.

Limitation: Comparator trial in diabetes, not a UK obesity tablet study.

What this means for a UK reader Useful for showing oral semaglutide's diabetes evidence base against another oral diabetes medicine.
PubMed abstract
Cardiovascular outcomes trial

PIONEER 6

Oral semaglutide cardiovascular outcomes

High outcomes-trial strength
CV non-inferiorMain signal
n=3183Scale/context
MedicineRybelsus / oral semaglutide
Moleculesemaglutide
JurisdictionGlobal
Use studiedType 2 diabetes with high cardiovascular risk

Population: People with type 2 diabetes at high cardiovascular risk.

Design: Event-driven, randomised, double-blind, placebo-controlled cardiovascular outcomes trial.

Sample and duration: 3183 enrolled participants. Event-driven follow-up.

Main result: The primary cardiovascular outcome occurred in 3.8% of the semaglutide group and 4.8% of placebo in the ACC summary.

Weight or metabolic signal: Not primarily a weight-loss study.

Safety read: Showed cardiovascular non-inferiority to placebo for the primary outcome.

Limitation: Cardiovascular safety trial in diabetes, not an obesity efficacy trial.

What this means for a UK reader Important because oral semaglutide is not only a weight-change story; cardiovascular safety evidence also matters.
PubMed / ACC clinical trial summary
Phase 3 trial

ATTAIN-1

Orforglipron obesity phase 3 trial

High trial strength
-11.2% weightMain signal
n=3127Scale/context
MedicineFoundayo / orforglipron
Moleculeorforglipron
JurisdictionGlobal / US relevance
Use studiedObesity without diabetes

Population: Adults with obesity and without diabetes.

Design: Multinational, randomised, double-blind phase 3 trial of orforglipron 6 mg, 12 mg or 36 mg versus placebo.

Sample and duration: 3127 randomised participants. 72 weeks.

Main result: Mean body-weight change at week 72 was -7.5%, -8.4% and -11.2% with orforglipron 6, 12 and 36 mg versus -2.1% with placebo.

Weight or metabolic signal: All tested doses reduced body weight significantly versus placebo.

Safety read: Adverse-event profile was described as consistent with GLP-1 receptor agonists in the PubMed abstract.

Limitation: Trial evidence and U.S. approval do not automatically create UK access.

What this means for a UK reader Central evidence for why Foundayo matters as a U.S. oral GLP-1 development while remaining separate from current UK availability.
PubMed / NEJM abstract
Phase 3 trial

ACHIEVE-1

Orforglipron in early type 2 diabetes

High trial strength
-1.3 to -1.6% HbA1cMain signal
n=559Scale/context
MedicineFoundayo / orforglipron
Moleculeorforglipron
JurisdictionGlobal / US relevance
Use studiedType 2 diabetes

Population: People with early type 2 diabetes.

Design: Phase 3 trial of oral orforglipron in early type 2 diabetes.

Sample and duration: 559 people are reported in public summaries. 40 weeks in public summaries..

Main result: Public summaries report HbA1c reductions of about 1.3 to 1.6 percentage points from a baseline around 8%.

Weight or metabolic signal: Weight and glycaemic outcomes both contribute to the orforglipron evidence story.

Safety read: Needs continued label and post-marketing review as the approved product history develops.

Limitation: Diabetes trial; UK availability and UK prescribing status still require UK regulator/access evidence.

What this means for a UK reader Shows orforglipron is not only an obesity story, but the UK reader still needs country-specific access framing.
PubMed abstract
Regulatory approval

FDA Foundayo approval

U.S. approval for orforglipron

Primary regulatory source
FDA approvedMain signal
1 Apr 2026Scale/context
MedicineFoundayo
Moleculeorforglipron
JurisdictionUS
Use studiedObesity / overweight with weight-related comorbidity

Population: Adults with obesity or adults with overweight and at least one weight-related comorbid condition.

Design: FDA approval announcement and approved-use context.

Sample and duration: Not a clinical trial card. Approval announced 1 April 2026..

Main result: FDA approved Foundayo for use with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in eligible adults.

Weight or metabolic signal: Approval is based on the submitted clinical evidence package, not a single outcome in this card.

Safety read: Use the FDA label for prescribing, contraindication and adverse-reaction detail.

Limitation: U.S. approval is not UK approval, UK launch or UK access.

What this means for a UK reader This is the strongest source for saying Foundayo is U.S.-approved, and also the reason the page must label the country every time.
FDA announcement
Regulator safety update

MHRA February 2026 semaglutide safety update

NAION safety signal

Primary UK safety source
NAION warningMain signal
UK safetyScale/context
MedicineRybelsus, Wegovy, Ozempic
Moleculesemaglutide
JurisdictionUK
Use studiedSafety monitoring

Population: People taking semaglutide products.

Design: MHRA safety communication.

Sample and duration: Not a clinical trial card. Published 25 February 2026..

Main result: MHRA safety material describes very rare reports of NAION with semaglutide and recommends urgent specialist review for sudden vision loss.

Weight or metabolic signal: Not a weight or HbA1c outcome source.

Safety read: This is a safety-source card; it belongs beside trial evidence, not underneath it.

Limitation: Safety communications do not estimate individual risk for a specific reader.

What this means for a UK reader Essential for UK pages because evidence authority includes safety updates, not only effectiveness headlines.
MHRA safety roundup
Regulator safety update

MHRA Rybelsus formulation transition

Rybelsus medication-error risk

Primary UK safety source
Dose-confusion riskMain signal
UK safetyScale/context
MedicineRybelsus
Moleculeoral semaglutide
JurisdictionUK
Use studiedMedication-error prevention

Population: People taking or dispensing Rybelsus during the formulation transition.

Design: MHRA safety communication.

Sample and duration: Not a clinical trial card. Published December 2025..

Main result: MHRA highlighted the move to lower stated strengths because the new formulation has higher bioavailability, creating a medication-error risk if strengths are compared incorrectly.

Weight or metabolic signal: Not a weight or HbA1c outcome source.

Safety read: Key practical safety point: lower stated tablet strengths should not be compensated for by taking extra tablets.

Limitation: Transition update, not a general efficacy study.

What this means for a UK reader A UK-specific evidence item that turns Rybelsus from a product name into a real-world medication-safety topic.
MHRA safety roundup

What is most useful in the UK?

The strongest UK-specific evidence in this first version is PIONEER REAL UK plus MHRA safety material. The strongest global oral-weight-loss evidence is OASIS and ATTAIN, but those have to be interpreted through UK licensing and access reality.

Current UK oral anchor

Rybelsus remains the practical UK oral GLP-1 anchor in the diabetes context.

US oral weight-loss momentum

OASIS 4 and Foundayo matter, but they do not by themselves create UK availability.

Safety belongs beside efficacy

MHRA NAION and Rybelsus transition updates are part of the evidence picture.

Real-world use is not a shortcut

Real-world data helps explain practice, but trial design and patient mix still matter.

Source register

This table is the audit trail for the library. It will expand as new trials, labels, regulator updates and UK evidence appear.

Evidence itemTypeJurisdictionSourceSource date
PIONEER REAL UK UK real-world study UK PubMed abstract 2024-09-24
IGNITE US real-world study US PMC article / real-world review context 2021-09-08
OASIS 1 Phase 3 trial Global PubMed / Lancet abstract 2023-06-23
OASIS 4 Phase 3 trial Global / US relevance PubMed / ACC summary 2025-09-18
PIONEER 1 Phase 3 trial Global Clinical review / PubMed-linked data 2019-06-11
PIONEER 2 Head-to-head trial Global PubMed abstract 2019-09-17
PIONEER 6 Cardiovascular outcomes trial Global PubMed / ACC clinical trial summary 2019-06-11
ATTAIN-1 Phase 3 trial Global / US relevance PubMed / NEJM abstract 2025-09-17
ACHIEVE-1 Phase 3 trial Global / US relevance PubMed abstract 2025-06-20
FDA Foundayo approval Regulatory approval US FDA announcement 2026-04-01
MHRA February 2026 semaglutide safety update Regulator safety update UK MHRA safety roundup 2026-02-25
MHRA Rybelsus formulation transition Regulator safety update UK MHRA safety roundup 2025-12-17

How to use this evidence

Use the evidence cards to check what each source can support. A trial can support an efficacy or safety discussion, a regulator source can support approval or safety wording, and a U.S. approval source cannot prove UK access.

Evidence type shows whether the item is a trial, real-world study, label or regulator update.
Jurisdiction keeps UK evidence, U.S. approval material and global trial data separate.
Limitations show what readers should not infer from the source.
Source links connect each card to the supporting publication or regulator page.

Editorial boundary

This library is informational and does not provide medical advice, prescribing advice or a treatment recommendation. A UK reader should use it to understand the evidence landscape, then use regulated clinical routes for personal decisions.